We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Since taking the helm as CEO of GPhA last September, Ralph Neas was thrown into the fire, immediately facing a drug shortage crisis, generic user fee program negotiations and FDA development of a biosimilars review pathway and user fee program (Generic Line, Sept. 14, 2011).